PT-141 nasal spray 2018 status explained: no FDA-approved nasal product existed, why Palatin dropped the spray, and how it compares to injections.
In 2018, there was no FDA-approved PT-141 nasal spray in the United States, and no nasal bremelanotide product was legally sold anywhere. The developer had already abandoned the intranasal formulation years earlier in favor of a subcutaneous injection, which the FDA approved in June 2019 under the brand name Vyleesi. Most people searching for a nasal version that year landed on bodybuilding forums, gray-market peptide websites, and decade-old clinical trial reports instead of a pharmacy shelf.
What PT-141 Is, in Plain Terms
PT-141 is the research name for bremelanotide, a synthetic cyclic peptide derived from Melanotan II. It acts on melanocortin receptors in the brain, mainly MC4R, and is thought to influence sexual desire through the central nervous system rather than through blood flow.
That mechanism is what made PT-141 interesting in the first place: it looked like a desire-pathway drug rather than a circulation drug like Viagra.
- Developer: Palatin Technologies.
- Original research targets: erectile dysfunction, later female sexual dysfunction.
- Approved form today: a 1.75 mg subcutaneous injection for premenopausal women with hypoactive sexual desire disorder (HSDD).
- Approved nasal form: none, in 2018 or now.
The 2018 Timeline: Why the Nasal Spray Disappeared
An intranasal bremelanotide spray was never a dead-end idea. It was an early-stage idea that lost out to a delivery method that worked more predictably.
| Period | What happened with PT-141 |
|---|---|
| Late 1990s to early 2000s | Melanotan II, then PT-141, are studied; early human trials test both intranasal and injected routes. |
| Mid-2000s | Palatin runs Phase 2 trials of an intranasal bremelanotide spray for erectile dysfunction and female sexual dysfunction. |
| Late 2000s | Nasal development is set aside. The program shifts to subcutaneous bremelanotide because absorption and tolerability are easier to manage. |
| 2015 to 2018 | Phase 3 RECONNECT trials test the injection in premenopausal women. In 2018 the drug is still investigational. |
| June 2019 | The FDA approves bremelanotide injection under the brand name Vyleesi. |
By 2018 the nasal spray was history, not a product quietly moving through development.
PT-141 Nasal Spray vs Injection
Anyone comparing the two routes in 2018 was really comparing a discontinued research formulation with an investigational injection. The breakdown below shows why that comparison turned out the way it did.
| Factor | Intranasal (studied, never approved) | Subcutaneous injection (approved 2019) |
|---|---|---|
| Absorption | Variable; affected by technique, congestion, and formulation | Consistent and predictable |
| Doses reported in trials | Roughly 10 to 20 mg per dose | 1.75 mg per dose |
| Nausea at working doses | More frequent | Common but dose-limited by design |
| Legal status in 2018 | Not approved; sold only as a research chemical | Not yet approved; investigational |
| Legal status today | No approved nasal product exists | Prescription only |
The nasal lining is a poor barrier for larger peptides, which is the core reason the injected version won. A pt-141 nasal spray vs injection comparison in 2018 usually favored the injection on consistency, even before approval.
What People Were Actually Buying in 2018
Because no legitimate nasal product existed, nasal sprays sold online in 2018 were almost always labeled for research use only, not for human consumption. Those vials came from unregulated suppliers with no guarantee of purity, sterility, or actual peptide content.
A pt-141 peptide nasal spray purchased from a gray-market site could contain the wrong peptide, the wrong concentration, or bacterial contamination that has no business in a nasal passage.
Forum threads titled how to make pt-141 nasal spray typically describe dissolving peptide powder in sterile or bacteriostatic water and transferring it into a metered spray bottle. That homemade route skips the sterility testing, pH control, and preservative requirements that real nasal products must meet. Anecdotal pt-141 peptide nasal spray reviews on message boards are not evidence of safety or effectiveness, and many of them read like advertising.
Dosing: What Trials Used and Why the Numbers Differ
Early intranasal studies used far higher milligram doses than the injected product, because only a small fraction of a nasal dose reaches the bloodstream. Published trial doses for the nasal formulation were in the range of roughly 10 to 20 mg, compared with just 1.75 mg for the approved injection.
There was never an official nasal dosing schedule, which is why search interest in pt-141 nasal spray dosage for men never produced a reliable answer. The approved injection is given under the skin of the abdomen or thigh at least 45 minutes before sexual activity, no more than once in 24 hours and no more than eight times per month. Anyone considering bremelanotide should discuss it with a healthcare professional instead of guessing a dose from a forum post.
Safety, Side Effects, and the Legal Picture
- Nausea is the most commonly reported side effect of bremelanotide.
- Flushing, headache, and injection-site reactions are also common.
- Bremelanotide can cause a temporary rise in blood pressure and a drop in heart rate, and it is contraindicated in people with uncontrolled hypertension or known cardiovascular disease.
- Repeated use has been linked to focal hyperpigmentation, a darkening of the skin, gums, or other areas.
- The drug is FDA-approved only for premenopausal women with acquired, generalized HSDD, not for men and not as a general libido booster.
Nasal formulations in trials tended to trigger more nausea at the doses needed to work, which is another reason the spray was shelved.
The Bottom Line for Anyone Searching for PT-141 Nasal Spray 2018 Info
PT-141 nasal spray was an abandoned research formulation in 2018, not a product anyone could legally buy. The only FDA-approved form of bremelanotide is a prescription injection approved in 2019, and it is cleared for a narrow group of patients. Peptide nasal sprays sold online are unregulated research chemicals, so using one means accepting unknown purity, unknown dose, and unknown risk. If you have questions about bremelanotide for yourself or a partner, a licensed healthcare provider is the right place to start.
Frequently Asked Questions
Was PT-141 nasal spray available in 2018?
No. There was no FDA-approved PT-141 nasal spray in 2018, and the intranasal formulation had already been dropped by its developer in favor of an injection. Bremelanotide was still an investigational drug that year. The FDA approved the injectable version, Vyleesi, in June 2019.
Why was the PT-141 nasal spray discontinued?
Nasal absorption of the peptide was inconsistent, so trials needed much larger doses than the injected form. Those higher doses came with more nausea and blood pressure effects. The subcutaneous injection delivered more predictable blood levels at 1.75 mg, so the company moved its development program there.
Is PT-141 nasal spray legal to buy in the US?
No approved nasal bremelanotide product exists in the United States, so any nasal spray sold online is an unapproved research chemical rather than a legal consumer product. The only FDA-approved form of PT-141 is the prescription injection Vyleesi, cleared for premenopausal women with hypoactive sexual desire disorder. Gray-market peptides come with unknown purity, dose, and sterility.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.